Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Investigate the Differential Influence of Prior Chemotherapy on the Efficacy of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (IIIB, IV) With or Without EGFR Gene Mutation

NCT01204307 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.

NCT NCT01204307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01204307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Investigate the Differential Influence of Prior Chemotherapy on the Efficacy of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (IIIB, IV) With or Without EGFR Gene Mutation
Lead sponsor
Chang Gung Memorial Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2010
Completion date
June 30, 2015
Enrollment
101 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-squamous non-small cell lung cancer